Research analysts at William Blair lowered their Q2 2026 earnings estimates for J.Jill in a report released on Thursday, ...

Stock analysts at William Blair issued their FY2026 earnings per share estimates for shares of LENZ Therapeutics in a ...

In a report released today, Andy Hsieh from William Blair maintained a Hold rating on BioAge Labs, Inc. (BIOA – Research Report). The company’s ...

Fintel reports that on March 21, 2025, William Blair downgraded their outlook for Valmont Industries (NYSE:VMI) from ...

Fintel reports that on March 20, 2025, William Blair downgraded their outlook for Beacon Roofing Supply (NasdaqGS:BECN) from ...

Emerging markets present a landscape of opportunity for equity investors despite macroeconomic headwinds. Click to read.

As Klarna wins installment lending for the retail giant's OnePay app, rival Affirm seeks to downplay the loss.

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...

The note emphasized that Palantir shares declined 10% following a 4% selloff in the Nasdaq, and if the broader market ...

Palantir (PLTR) was upgraded to Market Perform from Underperform by William Blair, following the recent share price decline by the data analysis and artificial intelligence software firm.

The embedded finance company, which posted a loss last year, hired Citigroup to explore its strategic options and named an ...